| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 27.83▲ | 28.17▼ | 28.20▼ | 29.58▼ | 28.96▼ |
| MA10 | 27.94▲ | 28.23▼ | 28.13▼ | 30.43▼ | 27.58▲ |
| MA20 | 28.09▼ | 28.20▼ | 28.82▼ | 28.83▼ | 27.38▲ |
| MA50 | 28.17▼ | 29.28▼ | 30.30▼ | 27.42▲ | 22.33▲ |
| MA100 | 28.23▼ | 30.45▼ | 29.54▼ | 26.74▲ | 19.35▲ |
| MA200 | 29.18▼ | 29.30▼ | 28.45▼ | 22.85▲ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.024▼ | 0.057▲ | 0.005▲ | -0.197▼ | 0.026▲ |
| RSI | 46.995▼ | 37.592▼ | 33.363▼ | 46.376▼ | 55.806▲ |
| STOCH | 21.675 | 51.425 | 40.140 | 34.268 | 58.835 |
| WILL %R | -27.451 | -56.471 | -83.333▼ | -80.130▼ | -61.029 |
| CCI | -20.200 | -135.608▼ | -107.519▼ | -58.141 | 44.602 |
|
Thursday, May 14, 2026 01:24 PM
Perry to its Board of Directors. 2026 Annual General Meeting Results The Company’s shareholders approved all agenda items. The shareholders approved the 2025 Annual Report including the 2025 Annual ...
|
|
Thursday, May 14, 2026 01:06 PM
Perry to its Board of Directors.
|
|
Monday, May 11, 2026 01:21 PM
Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026Licaminlimab PREDICT-1 Trial in Active Site ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 19/05/26 | 28.20 | 29.3799 | 27.685 | 27.96 | 289,898 |
| 18/05/26 | 30.70 | 30.70 | 27.77 | 28.07 | 389,770 |
| 15/05/26 | 29.89 | 30.56 | 29.50 | 30.29 | 250,914 |
| 14/05/26 | 31.29 | 31.29 | 29.94 | 30.22 | 242,365 |
| 13/05/26 | 30.51 | 31.39 | 29.52 | 31.37 | 686,390 |
| 12/05/26 | 32.15 | 32.47 | 30.28 | 30.41 | 526,278 |
| 11/05/26 | 34.00 | 34.13 | 32.42 | 32.65 | 625,529 |
| 08/05/26 | 31.02 | 32.76 | 30.95 | 32.64 | 484,209 |
| 07/05/26 | 31.00 | 31.33 | 29.46 | 31.09 | 581,635 |
| 06/05/26 | 27.98 | 29.715 | 27.98 | 29.58 | 263,894 |
|
|
||||
|
|
||||
|
|